Podcast thumbnail for 科化未來

科化未來

Claim This Podcast

by EternalOne BioIndustry Club

13 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇹🇼

Podcast Overview

歡迎來到科化未來podcast頻道! 我們是EternalOne BioIndustry Club,由一群台灣海外年輕生技學子和產業人士於 2020 年底成立的線上生技社群,我們希望建立一個由台灣生技專業人士組成的全球網絡,定期進行職涯經驗分享和討論論壇,結合社交活動和深度交流的工作坊及師徒制輔導計劃。 在這個頻道中,我們將會定期分享生技產業公司介紹及我們社團舉辦的Career Talk活動訪問,來使聽眾們可以對現今生技產業現況能有更多的了解與認識。歡迎任何對於生技產業有興趣並想要更參與到我們更多的活動或是討論的人加入我們的討論群 (Telegram: https://t.me/eternalone_bioindustry_chat) 與我們互動,一同分享自己的見解。 想要參與我們的觀眾朋友們歡迎透過下面的連結來參與我們的活動: 官方網站: https://eternalonetw.com/ LinkedIn: https://www.linkedin.com/company/eternalone-bioindustry-club Facebook: https://www.facebook.com/EternalOneBioIndustryClub/ IG: https://www.instagram.com/eternalone.bioindustry.club/

Language

🇨🇳

Publishing Since

6/30/2021

1 verified contact email on file for 科化未來

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

Recent Episodes

Episode thumbnail for EP12 – Biogen 阿茲海默新藥 Aduhelm 爭議

January 9, 2022

EP12 – Biogen 阿茲海默新藥 Aduhelm 爭議

<p>2021 年 6 月 7 日被美國食品和藥物管理局 (<a href="https://www.biospace.com/employer/401530/food-and-drug-administration-fda-/">Food and Drug Administratio</a>n,FDA) 加速批准了由美國 Biogen (百健) 和日本 Eisai (衛采) 藥廠共同研發的 Aduhelm (Aducanumab 單株抗體)。這可是自 2003 年以來首次批准可用於治療阿茲海默症 (Alzheimer’s disease) 之新型療法。本是令人歡欣鼓舞的醫藥生技產業大事,然而卻引發各方爭論其藥物之有效性以及藥價制定之合理性,並連帶有 3 名 FDA 專家因而請辭。究竟這次事件的關鍵爭議在哪,又有哪些可以參考的合理藥價制定分析方法呢?讓我們一起聽下去吧!</p>

Episode thumbnail for EP11 – 進軍AI的手持式超音波儀器佼佼者 ButterflyiQ

December 28, 2021

EP11 – 進軍AI的手持式超音波儀器佼佼者 ButterflyiQ

<p><strong>大家對超音波檢查應該都不陌生吧?它是醫院診間中最常見的檢查之一,可以在短時間內提供醫生許多診斷資訊。在診間的診察床上,醫生拿著探頭輕壓著你的肚皮移動,聚精會神地看著儀器螢幕,你的耳邊時不時傳來切換掃描模式的按鍵聲響,想著剛剛醫生抹在肚皮上的東西還真的有點冰。但你知道嗎,作為手持式超音波儀器中的佼佼者的ButterflyiQ,整在領導一場超音波儀器的革新!就讓我們一起看下去吧~</strong></p>

Episode thumbnail for EP10 – 新型聯合疫苗的發展者 Novavax

December 4, 2021

EP10 – 新型聯合疫苗的發展者 Novavax

<p>Novavax成立於西元1987年,為一家總部設置於美國馬里蘭州 Gaithersburg 之疫苗公司,Novavax的宗旨為發現並開發可用於預防嚴重傳染病之商業化創新疫苗來促進全球健康水準的提高。這間在疫苗開發有著多年經驗的公司,卻在這次的新冠疫苗開發中,意外造成股價大跌。究竟發生什麼事了呢?讓我們一起看下去吧~</p>

13 total episodes available

Deep-dive analytics for 科化未來

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is 科化未來?

歡迎來到科化未來podcast頻道!

我們是EternalOne BioIndustry Club,由一群台灣海外年輕生技學子和產業人士於 2020 年底成立的線上生技社群,我們希望建立一個由台灣生技專業人士組成的全球網絡,定期進行職涯經驗分享和討論論壇,結合社交活動和深度交流的工作坊及師徒制輔導計劃。

在這個頻道中,我們將會定期分享生技產業公司介紹及我們社團舉辦的Career Talk活動訪問,來使聽眾們可以對現今生技產業現況能有更多的了解與認識。歡迎任何對於生技產業有興趣並想要更參與到我們更多的活動或是討論的人加入我們的討論群 (Telegram: https://t.me/eternalone_bioindustry_chat) 與我們互動,一同分享自己的見解。

想要參與我們的觀眾朋友們歡迎透過下面的連結來參與我們的活動: 官方網站: https://eternalonetw.com/ LinkedIn: https://www.linkedin.com/company/eternalone-bioindustry-club Facebook: https://www.facebook.com/EternalOneBioIndustryClub/ IG: https://www.instagram.com/eternalone.bioindustry.club/

How often does this podcast release new episodes?

This podcast updates daily.

Where can I listen to this podcast?

This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.